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ABSTRACT
The new gene editing system CRISPR/Cas9, composed of a complex
composed of a guide RNA and the Cas9 endonuclease, promises to revolutionize
biological research and potentially allow clinicians to directly modify patient DNA in
vivo. While its applications in the treatment of genetic diseases and in modifying
immune cells for immunotherapy are currently being explored, CRISPR/Cas9’s
potential utility as a modular system for targeting tumor-specific mutated
sequences has not as of yet been explored. While CRISPR/Cas9 is specific enough to
target small insertions and deletions or gross chromosomal rearrangements, it is
not specific enough to reliably restrict editing to single nucleotide variants (SNVs),
which compose the majority of cancer-associated mutations. By searching for
tumor-specific SNVs that generate new protospacer adjacent motifs (neoPAMs), a
short sequence that must be present next to the target sequence in order for Cas9 to
cleave at the target site, gene editing can theoretically be restricted to tumor cells
bearing the mutation of interest. This capability could permit the insertion of suicide
genes, pro-inflammatory cytokines, or immunogenic epitopes in a tumor-specific
manner. The results shown here demonstrate the importance of taking into account
guide RNA efficiency when selecting a target site. New target sites in the tumor cell
line FABF with high predicted guide RNA efficiencies are identified and discussed.
Finally, strategies for maximizing the antitumor effect of neoPAM-restricted gene
editing are described and compared.
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INTRODUCTION
Tumors contain, and are driven by, somatic mutations1. Chief among these
are the single nucleotide variations (SNVs), point mutations found in all known
human cancers1,2. While some somatic mutations are acquired later in neoplastic
development and hence are not shared by all cancer cells in a tumor (the so-called
branch mutations), a subset are acquired before or during the process of neoplastic
transformation and hence are shared by almost all cancer cells (the so-called trunk
mutations)3. These trunk mutations are unique identifiers of tumor cells, but no
methods are presently available to use trunk mutations as a basis to therapeutically
target tumor cells for destruction.
Sequence-specific gene editing may potentially allow such a capability.
Nucleases such as zinc-finger nucleases (ZFNs) and transcription activator-like
effector nucleases (TALENs) provide sufficient sequence specificity to in theory
permit the selective modification of cancer-specific mutated sequences, but
inefficiencies in nuclease design and production have severely limited their use in a
clinically relevant context4,5. The new CRISPR/Cas9 gene editing system is both
more efficient and far easier to use than these older systems, and hence may soon be
widely employed in human therapeutic gene editing6-8.
Two RNA molecules, the CRISPR RNA (crRNA) and trans-acting CRISPR RNA
(tracrRNA) interact to form the complete guide RNA (gRNA) molecule. The gRNA
then forms a complex with the Cas9 endonuclease to form the complete Cas9
ribonucleoprotein (Cas9 RNP). Biochemical manipulations permit the use of a single
guide RNA (sgRNA) composed of a single sequence that folds on itself to mimic the
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crRNA:tracrRNA interaction, vastly simplifying gene editing6-9. The approximately
20 nucleotides at the 5’ end of the gRNA restrict the nuclease activity of Cas9 to
target DNA with sufficient sequence complementary as determined by Watson-Crick
base pairing8,9. Sequence complementarity is insufficient to mediate doublestranded break (DSB) induction, however - a short motif, called a protospacer
adjacent motif (PAM), must be present immediately next to the target sequence to
permit nuclease activity8,9. The canonical PAM of the most commonly used Cas9
isoform from Streptococcus pyogenes (SpCas9) is 5’-NGG-3’, where N can be any
nucleotide6-9. A guanine in the first position is generally preferred, but not strictly
required10.
The specificity of wild-type Cas9 is not perfect – mismatches between the
target sequence and gRNA are sometimes tolerated6,7. PAM proximal mismatches
and strings of mismatches are not well tolerated, while isolated, PAM distal
mutations do not often affect Cas9 activity10-12. Further, off-target PAM sequences
have been observed for wild-type SpCas9, with 5’-NAG-3’ constituting the vast
majority of the off-target PAM sequences10,11.
The Cas9-induced DSB can be repaired via two main pathways. The first is
error-prone non-homologous end joining (NHEJ) whereby the blunt ends of the DNA
are directly ligated together, often generating gene-inactivating small insertions and
deletions (indels)6,8,9. Alternatively, DSBs may be repaired by homology-directed
repair (HDR) whereby a DNA strand homologous to the damaged strand is used as a
template for precise repair. Transfection with exogenous DNA sequences containing
homology arms at the 5’ and 3’ ends matching either side of the Cas9 target site
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permits the insertion, mediated by HDR, of virtually any DNA sequence at any locus
with high fidelity6,8,9.
Multiple groups have made modifications to SpCas9 to enhance its specificity
and versatility. Foremost among these are the nickases and nuclease-null variants,
which knock out either one or both of the catalytic subunits responsible for strand
breakage respectively13. Single or paired nickases can be used to generate either
single-stranded breaks (SSBs) or DSBs with large overhangs, which both severely
limit the frequency of NHEJ and thereby bias editing towards HDR14,15. Further,
nuclease-null variants, referred to as dead Cas9 or dCas9, can be used to activate or
repress transcription or visualize genomic loci16,17. Other groups have rationally
modified SpCas9 to limit its non-specific contacts with DNA, thereby improving its
specificity18,19. Finally, recent work has shown that the use of truncated guide RNAs
can significantly reduce off-target DSB events without sacrificing on-target
activity20. Sufficiently truncating the guide RNA can eliminate DSB induction without
interfering with Cas9’s ability to bind target sites, permitting multiplexed gene
editing and transcriptional modulation from the same protein21.
Recent work has shown that an SNP that generates a novel PAM sequence
can restrict Cas9-mediated gene editing to the SNP-containing chromosome, with no
detectable off-target editing at the other chromosome22. This suggests a cancerspecific point mutation that generates a new PAM, a neoPAM, can restrict Cas9mediated genome editing to cancer cells alone. While the target sequence
complementary to the gRNA would be present with zero mismatches in both tumor
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and healthy tissue, only tumor cells would have the necessary adjacent neoPAM
sequence to permit recognition and DSB induction by Cas9.
The cancer-specific DSB generated by neoPAM restriction can be used to
mediate the insertion of new genes via HDR. Even if neoPAM restriction is truly
tumor-specific, it is unlikely that all cancer cells will be targeted due to the low
efficiencies of in vivo delivery and HDR23,24. Cytotoxic elements that exert potent
bystander effects whereby successfully transformed tumor cells induce cell death or
growth inhibition in nearby cells may solve this problem. One well-studied class of
genes that carry this property is the suicide genes. These genes convert non-toxic
prodrugs to toxic metabolites, and their selective expression in cancer cells permits
tumor-specific cytotoxicity25-28. The best studied of these are the herpes simplex
virus thymidine kinase/ganciclovir (HSV-TK/GCV) and cytosine deaminase/5fluorocytosine (CD/5-FC) systems, though other effective systems exist28.
In the HSV-TK/GCV system, the thymidine kinase from herpes simplex virus
monophosphorylates nucleoside analogs like ganciclovir, an analog of 2’deoxyguanosine bound to an acyclic sugar. The monophosphorylated intermediate
is fully phosphorylated by endogenous enzymes and incorporated into DNA by
endogenous polymerases, whereupon its incomplete sugar ring induces termination
of chain elongation and eventually cell death through ligand-independent death
receptor

aggregation

and

subsequent

apoptosis29-31.

Because

ganciclovir

triphosphate is triply negatively charged, it cannot diffuse across cell membranes
and hence relies on gap junctions to exert a bystander effect32. In tumor cells that
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are gap junction deficient, the bystander effect of the HSV-TK/GCV system can be
restored through pharmacological induction of gap junctions35.
Multiple attempts have been made to modify the HSV-TK enzyme to both
increase its sensitivity to ganciclovir and reduce its affinity for its intended
substrate29. These efforts have produced mutants that dramatically increase
transduced tumor cell sensitivity to ganciclovir, occasionally by over two orders of
magnitude34. One rationally designed mutant in particular, TK007, introduces a
targeted A to H mutation at position 168 that markedly reduces the enzyme’s
affinity for deoxythymidine while retaining its affinity for ganciclovir, thereby
enhancing its efficiency35. This modification dramatically improves TK007’s killing
efficiency and its bystander effect both in vitro and in vivo in a murine xenograft
model36.
The CD/5-FC system uses cytosine deaminase from either E. coli or S.
cerevisiae to convert the nontoxic prodrug 5-fluorocytosine into the widely used
chemotherapeutic 5-fluorouracil (5-FU). 5-FU is readily converted in situ by
endogenous enzymes to its monophosphorylated form 5-fluoro-2’-deoxyuridine-5’monophosphate (5-FdUMP) which irreversibly inhibits the essential enzyme
thymidylate synthetase or to its triphosphorylated form 5-fluorouridine-5’triphosphate which can be incorporated into RNA and subsequently inhibits nuclear
RNA processing28. While these phosphorylated molecules are restricted to the cells
in which they were produced, 5-FU can freely diffuse across cell membranes due to
its neutral charge and small size. Thus, the CD/5-FU system mediates a significantly
more potent bystander effect than the HSV-TK/GCV system37. Further, yeast CD,
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which has a significantly lower Km value for 5-FC than bacterial CD, is a far smaller
gene than either HSV-TK or bacterial CD28,38.
Both of these systems are somewhat limited in that the suicide enzyme is
localized to successfully transduced tumor cells. Intercellular trafficking
mechanisms by which the enzymes could be transferred between neighboring cells
after expression have the potential to markedly increase the efficacy of these
systems. One such modification, a fusion of the viral intercellular trafficking protein
VP22 to HSV-TK, permitted the transfer of the fusion protein from a donor
transfected cell line to co-cultured gap junction-negative neuroblastoma cells,
mediating extensive cell death in this untransfected, bystander effect-impaired cell
line39. This fusion protein was later demonstrated to modestly increase sensitivity
to ganciclovir in a human epithelial cell line40. A similar fusion protein was
constructed using bacterial CD that also mediated increased sensitivity to its
prodrug substrate compared to its wild type counterpart41.
In contrast to gene therapy strategies that rely on enzymes and their
cytotoxic metabolites to mediate tumor cell death, tumor-targeted immune gene
therapies modify tumor cells to express cytokines or ligands that stimulate an
antitumor immune response42. These techniques can initiate a new immune
response against tumor-associated antigens or can help overcome tumor-mediated
immunosuppression. The stunning effectiveness of immune checkpoint blockade
supports the notion of leveraging the immune system to fight cancer. These
antibody-based therapeutics function by unleashing preexisting immune responses
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against tumor neoantigens, lending support to the notion that enhancing tumor
immunogenicity through gene therapy may be an effective therapeutic modality43-46.
The earliest studies into immunoactivatory gene therapy focused on the
transfection of inflammatory Th1 cytokines known to be crucial to the adaptive
antitumor immune response. The most prominent of these cytokines are
interleukin-2 (IL-2) and interferon-γ. IL-2 is essential for CD8+ and CD4+ T cell
proliferation, differentiation, and effector function acquisition47,48. The acquisition
of effector functions in vitro impairs IL-2 secretion and limits a sustained antitumor
immune response in vivo49, while IL-2 secretion by tumor cells overcomes the need
for CD4+ T cell help in the generation of an MHC I-restricted, cytotoxic lymphocyte
(CTL)-mediated antitumor response50. In a murine fibrosarcoma model, IL-2
secretion by CMS-5 tumor cells induced a CTL response against both the parental
and IL-2 secreting cell lines. Mice that rejected IL-2 secreting CMS-5 were protected
against rechallenge with a tumorigenic dose of parental CMS-5, indicating the
antitumor immune response was specific for tumor antigens51. These results have
relevance for human patients, as immunization of neuroblastoma-bearing children
with autologous unirradiated tumor cells transduced with adenoviral DNA
expressing IL-2 magnified CTL killing of autologous tumor cells and generated a
local CD4+ helper cell-mediated inflammatory environment52. IL-2, while clearly
beneficial for the establishment and maintenance of an antitumor immune response,
is

also

responsible

for

the

activation

and

expansion

of

powerfully

immunosuppressive T regulatory cells (Tregs) in response to self-antigen53,54. Treg
activity and induction from naïve CD4+ T cells are known to be key mechanisms by
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which tumors escape the immune response55,56, and hence IL-2 secretion by tumor
cells is unlikely to be broadly sufficient for immune-mediated tumor rejection.
Interferon-γ, meanwhile, is crucial for cellular immunity and hence has a central
role in immune-mediated tumor control57. It is secreted by activated NK, NKT, Th1
helper cells, and CTLs and has a broad array of functions, including inducing MHC
Class I and Class II expression, promoting a Th1 cell phenotype, activating resident
macrophages, promoting tumor cell apoptosis and the release of pro-inflammatory
cytokines, and inhibiting angiogenesis57-65. It has been shown to augment the
expression of viral antigens in the nonimmunogenic sarcoma MCA 101, thereby
aiding in the generation of tumor-specific CTLs66. Further, interferon-γ may be
involved in the suppression of Treg proliferation mediated in part by interleukin-12
(IL-12), a cytokine secreted by activated Th1 and NK cells67, potentially limiting
Treg expansion driven by IL-2. These results provide a strong rationale for in vivo
tumor modification to induce intratumoral secretion of both interferon-γ and IL-2.
Other cytokines, in particular tumor necrosis factor, interferon-α, and IL-12,
are intimately involved in the antitumor innate and adaptive immune responses to
varying degrees68-76. Thus, immunoactivatory in vivo tumor gene modification
strategies may also induce the secretion of these cytokines either in combination
with interferon-γ, IL-2, and/or each other. However, as homologous recombination
efficiency decreases with increasing insert size77, the additional efficacy associated
with the expression of additional cytokines would need to be balanced against the
decreased number of successfully transformed cancer cells.
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A number of immunoactivatory ligands can also be used to enhance the
immunogenicity of tumors. Co-stimulatory ligands, namely B7-1, B7-2, and B7h, are
expressed on activated antigen-presenting cells (APCs) and bind either CD28 (in the
case of B7-1 and B7-2) or ICOS (in the case of B7h) on T cells. The CD28-B7
interaction is a necessary costimulatory signal for T cell activation; without it, TCR
engagement with the target peptide-MHC complex leads to anergy instead of
activation78-81. Hence, a paucity of costimulatory B7 expression on APCs may impair
the antitumor immune response by preventing T cell priming. In a variety of tumor
models, transfection of tumor cells with B7-1 or B7-2 leads to the activation of CD8+
and/or CD4+ T cell responses that can eradicate established tumors and provide
protection against the parental tumor cell line82-84. Hence, selective in vivo
modification to induce costimulatory ligand expression in tumor cells either alone
or in combination with pro-inflammatory cytokines may have clinical relevance.
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MATERIALS AND METHODS
Identification of FABF-specific neoPAMs – The murine tumor cell line FABF, a
cell line identified in the Srivastava lab, was used for the following studies. The FABF
exome had been sequenced previously and the data generously provided by Cory
Brennick. A program was written to identify point mutations that produced GG or
CC dinucleotides excluding GG dinucleotides where the wild type sequence was 5’AG-3’ or CC dinucleotides where the wild type sequence was 5’-CT-3’. If the
mutation produced a GG dinucleotide, the putative target sequence was retrieved
from the 21 nucleotides 5’ of the dinucleotide on sense strand in the UCSC Mus
musculus version mm10 reference genome. The first 20 nucleotides of this sequence
were converted to the corresponding RNA sequence and ordered as an sgRNA from
Sigma Aldrich. In contrast, if the mutation produced a CC dinucleotide, the putative
target sequence was retrieved by reconstructing the antisense strand from the 21
nucleotides 3’ of the dinucleotide in the mm10 reference genome85.
NeoPAM efficiency screen – The cleavage efficiency of putative sgRNAs was
predicted with the online CRISPR Efficiency Predictor tool. Any putative sgRNA with
a score above 7.5 were considered fit for further analysis.
Design and synthesis of donor DNA – The 500 nucleotides 5’ and 3’ of the
chosen target site were obtained from the mm10 reference genome85. The minimal
cytomegalovirus early/intermediate enhancer and promoter elements were
obtained from the sequence data of Plasmid #80802 in the Addgene database86. The
SV40 polyadenylation signal was obtained from the sequence data of Plasmid
#55764 in the Addgene database87. The chicken ovalbumin sequence was retrieved
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from entry P01012 in the Uniprot database88. Finally, an ER insertion sequence was
retrieved from the literature89. Donor DNA sequences were constructed in silico,
synthesized by GenScript, and quantified by a NanoDrop spectrophotometer.
Cell culture – FABF cells were grown in RPMI (Life Technologies)
supplemented with 10% heat-shocked fetal bovine serum, penicillin/streptomycin,
sodium pyruvate, non-essential amino acids, and β-mercaptoethanol (complete
RPMI). Cells were grown until they became 90% confluent, after which they were
trypsinized and either used in downstream applications or seeded into larger flasks.
When stocks needed to be made, cells were resuspended to between 2*106 and
8*106 cells/mL in complete RPMI supplemented with an additional 10% heatshocked fetal bovine serum and 10% DMSO and stored in cryopreservation tubes at
-80 °C. Cells were thawed by placing the cryopreservation tubes in a 37 °C water
bath for 1 minute or until fully thawed directly from the -80 °C freezer.
Cas9 RNP transfection – Lipofectamine CRISPRMAX (Thermofisher) was used
for all transfections. Manufacturer protocols were modified as follows: one day
before transfection, 5*104 FABF cells were seeded in the requisite number of wells
of a 24 well plate in 500 μL complete RPMI media such that the plates were between
30% and 70% confluent at the time of transfection. On the day of transfection, Cas9
v2 protein (ThermoFisher Scientific), sgRNA (Sigma Aldrich, custom synthesized),
and donor DNA (GenScript, custom synthesized) were thawed on ice. Opti-MEM
reduced serum media, Cas9 Plus reagent, and Lipofectamine CRISPRMAX (all
ThermoFisher Scientific) were moved from 4 °C and kept on ice until use. 25 μL of
Opti-MEM media was then added to two sterile Eppendorf tubes. 1250 ng Cas9 v2
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protein and 240 ng sgRNA were added to one of these tubes (Tube 1) while
concurrently 1.5 μL of Lipofectamine CRISPRMAX was added to the second tube
(Tube 2). Both of these tubes were briefly vortexed and 1 μL of Cas9 Plus reagent
was added to Tube 1. Both tubes were incubated at room temperature for 5
minutes, after which 300 ng of linear donor DNA was added to Tube 1. Tube 1 was
then briefly vortexed and its contents added to Tube 2, which was then vortexed
briefly and incubated at room temperature for 15 minutes. 50 μL of this mixture was
then added to the cells in a single well and mixed well. Cells were incubated for 1
day before the addition of an additional 750 μL of complete RPMI. On the second day
after transfection, media was removed, wells were washed with 1 mL PBS twice, and
500 μL of 37 °C of trypsin EDTA was added to each well and allowed to incubate at
37 °C for approximately 1 minute. Wells were then washed with 2 mL complete
RPMI and transferred to 14 mL Eppendorf tubes. The tubes were then diluted with
10-14 mL complete RPMI and spun down at 300 g for 5 minutes, resuspended with
10 mL complete RPMI, and plated.
sgRNA cleavage validation assay – Approximately 1*106 cells were lysed and
digested with Cell Lysis Buffer and Protein Degrader from the GeneArt® Genomic
Cleavage Detection Kit (Thermofisher). 2 μL of cell lysate was added to a PCR
reaction with 0.2 μM of each primer and the PCR master mix provided by the
Cleavage Detection Kit according to manufacturer protocols and cycled as follows:
10 min. @ 95 °C, 1 cycle; 30 sec. @ 95 °C and 30 sec. at the lowest primer T m – 5 °C
and 30 sec. at 72 °C, 40 cycles; 7 min. at 72 °C, 1 cycle; 4 °C hold. The PCR product
was concentrated and contaminating proteins and chaotropic salts removed with
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the PCR Clean-Up and Gel Extraction Kit (Takara Bio) according to manufacturer
protocols.

Purified

PCR

product

was

quantified

with

a

NanoDrop

spectrophotometer. 100 ng of DNA was then denatured, re-annealed, and digested
according to manufacturer protocols. 10 μL of the resulting solution was run on a
2% agarose gel at 50 V for 1 hour and visualized with a GelDoc imager (Bio-Rad
Laboratories).
B3Z coculture assay – FABF cells were trypsinized, resuspended, and counted
with an automatic hemocytometer and AO/PI staining according to standard
protocols. 200,000 FABF cells per group were then added to a 96 well round bottom
plate in 100 μL of complete RPMI. Semi-adherent B3Z cells were then resuspended
and counted via AO/PI staining with an automatic hemocytometer. 200,000 B3Z
cells were then added to the plates previously seeded with FABF in 100 μL of
complete RPMI such that each well contained 200 μL of media. Plates were
incubated at 37 °C for 20 hours. Plates were then spun at 931 g for 2 min and the
supernatant was decanted. Wells were gently washed twice with 200 μL PBS such
that the cells at the bottom of the well were not disturbed. 150 μL of a pre-prepared
solution of chlorophenol red-β-D-galactopyranoside (45.5 mg chlorophenol red-βD-galactopyranoside, 2.5 mL NP40, and 4.5 mL of 1 M MgCl2 in 500 mL of PBS) was
then added to each well and allowed to incubate at room temperature for 15
minutes. Each well was gently resuspended, avoiding the creation of air bubbles,
and 120 μL was transferred from each well to one of the wells of a 96 well flat
bottom plate. This plate was then incubated at 37 °C for 1 hour. This plate was then
transferred to a dark place shielded from light and incubated at room temperature
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for 24 hours. The plate was then read at 570 nm on an iMark microplate reader
(Bio-Rad Laboratories).
Peptide pulsing – 800,000 FABF cells were resuspended in 500 μL and pulsed
with either 1 or 10 μM of the peptide SIINFEKL in DMSO for one hour at 37 °C. After
pulsing, cells were washed three times with 10 mL of PBS.
Crude DNA extraction and PCR – 700,000 FABF cells were resuspended in 180
μL of 50 mM NaOH and moved into a PCR tube which was then incubated at 95 °C
for 10 minutes. 25 μL of 1 M Tris-HCl was then added to neutralize the solution. 5 μL
of this lysate was added to a Terra™ Direct Red Dye Premix (Takara Bio) reaction
with a 0.5 μM of each primer according to manufacturer recommendations. For
positive controls, the higher volume of either 10 ng of DNA or 0.1 μL of stock
solution was mixed in a Terra™ Direct Red Dye Premix reaction according to
manufacturer protocols with 0.5 μM of each primer. The reactions were held in hot
start mode for 10 minutes and subsequently cycled as follows: 2 min. @ 98 °C, 1
cycle; 10 sec. @ 98 °C and 15 sec. @ 56 °C and 2:30 @ 68 °C, 30 cycles; 4 °C hold. 5
μL of each reaction was then run on a gel with an agarose quantity sufficient to
resolve bands of the expected size(s) at 90 V for an hour.
High quality DNA extraction and PCR – The DNA of between 1*106 and 2*106
FABF cells was extracted with a DNeasy® Blood and Tissue Kit (Qiagen) according to
manufacturer protocols. The quantity of DNA was measured using a NanoDrop
spectrophotometer. 400 ng of extracted genomic DNA or 10 ng of purified plasmid
DNA was mixed with 0.5 μM of each primer and the remaining PCR components
according to established Long Amplification AccuTaq manufacturer protocols
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(Sigma Aldrich). Annealing temperatures were set at 5 °C below the lowest
annealing temperature for any given set of reactions. The reactions were then cycled
as follows: 2 min @ 98 °C, 1 cycle; 10 sec @ 96 °C and 15 sec @ annealing
temperature and 2:30 @ 68 °C, 30 cycles; 4 °C hold, indefinitely. 5 μL of each
reaction was then mixed with 5 μL of loading buffer and run on a gel with an
agarose quantity sufficient to resolve bands of the expected size(s) at 90 V for an
hour.
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RESULTS

Figure 1: Strategy for Tumor-Specific Gene Insertion. In normal tissue,
the sgRNA-Cas9 complex cannot cleave the target sequence because there is no PAM
immediately 3’ of the target site in the genomic DNA. In contrast, a tumor-specific
mutation creates a neoPAM immediately 3’ of the target site, allowing the same
sgRNA-Cas9 complex to cleave the DNA and generate a DSB. An exogenous donor
DNA sequence flanked with arms of homology to either side of the Cas9-generated
DSB is used by the cell as a template for repair via homologous recombination,
thereby precisely inserting the exogenous DNA into the malignant cell at the target
locus. Of the available target sites, Target Sequence 17 (Target17) was chosen
because of its low predicted levels of off-target effects (data not shown).
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Figure 2: Composition of Donor DNA Constructs. Three different donor
DNA constructs were designed and synthesized to identify an expression strategy
that would maximize the expression of SIINFEKL, an immunogenic peptide from
chicken ovalbumin that is recognized by a wide variety of well-characterized T cell
hybridomas89-91. SIINFEKL was chosen as a model antigen because the wide array of
SIINFEKL-specific hybridomas and transgenic T cell lines makes the detection of
SIINFEKL expression in an immunologically relevant context methodologically
simple90,91.
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In each construct, homology arms obtained from the sequences surrounding
the sgRNA target site flank the minimal cytomegalovirus early/intermediate
enhancer/promoter element and the SV40 polyadenylation signal. In the ER Insert
sequence, the ER insertion signal from the E3/19K adenovirus protein was attached
to the N-terminus of SIINFEKL to promote the insertion of the recombinant
polypeptide into the ER where MHC Class I loading occurs and thereby enhance
loading of SIINFEKL onto MHC Class I92,93. The ER insertion signal is not required for
peptide loading onto MHC Class I, as in its absence cytosolic peptide will be
transported to the lumen of the ER by the transporter associated with antigen
processing (TAP)94. In the Spacers sequence, the 15 amino acids N-terminal to
SIINFEKL and 11 amino acids C-terminal to SIINFEKL from the endogenous
ovalbumin sequence were included in the minigene sequence to account for the
possibility that the flanking sequences assist in peptide processing. Finally, the
TruncOVA sequence is a truncated ovalbumin sequence without the first 100 amino
acids. This polypeptide will not fold and will be degraded, releasing SIINFEKL into
the cytosol where it should be transported into the ER, loaded on MHC Class I, and
presented on the cell surface.
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Figure 3: No Donor DNA Construct Drives SIINFEKL Presentation. (a)
B3Z, a T cell hybridoma specific for SIINFEKL that produces LacZ upon TCR
engagement90, was cocultured with FABF cells transfected two days prior with
Englander
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Target17 sgRNA, Cas9, and the indicated donor DNA constructs. Negative controls
were FABF cells transfected with donor DNA alone. Naïve FABF was also pulsed
with SIINFEKL and cocultured with B3Z cells as a positive control as tumor cells will
take up peptide from the medium and present it on MHC Class I94. After a day of
coculture, cells were lysed and the lysate incubated with CRPG, a yellow compound
that is a substrate for β-galactosidase. CRPG turns red after cleavage by βgalactosidase, allowing detection of LacZ expression and hence TCR engagement by
measuring the lysate’s absorbance at 570 nm. While TruncOVA produced what
appears to be a moderate positive signal, its corresponding negative control group’s
signal is higher. To account for the possibility the negative control group’s signal
was artifactual, this experiment was repeated. (b) The same experiment as in (a)
except only TruncOVA was included in the assay and both the negative control and
experimental groups were assayed in five replicates. SIINFEKL-pulsed and naïve
FABF were only assayed in one replicate each. No signal was detected in either the
TruncOVA negative control or experimental group, demonstrating that the signal
seen in (a) was artifactual and no donor DNA constructs drive the presentation of
SIINFEKL at the FABF cell surface.
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(a)

(b)

Figure 4: NeoPAM Knock-In with Target17 Does Not Mediate Construct
Insertion at the Target Site. (a) A lack of presentation could have been because of
no construct insertion, no expression, or a defect in presentation. To identify which
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of these was the cause of the negative results in Figure 3, the homology arms
included in the donor DNA constructs were amplified from crude extract of ER
Insert, Spacers, and TruncOVA negative controls and experimental groups and from
purified donor DNA as a positive control. Since the homology arms are present in
both the donor DNA and FABF itself, amplification was expected to occur regardless
of the success of construct insertion. No insertion was expected to produce a 927 bp
band (black arrows), while insertion of ER Insert, Spacers, or TruncOVA was
expected to produce a 1623 bp band (blue arrow), a 1650 bp band (green arrow), or
a 2412 bp band (red arrow), respectively. In both the negative controls and
experimental groups for each individual construct, no band above 927 bp in size can
be detected, while positive controls produce bands of the expected size. Nonspecific
bands are likely due to the crude extract and hypersensitive polymerase used for
these experiments. (Lanes 1, 2, 3: ER Insert, Spacers, and TruncOVA negative
controls, respectively; Lanes 4, 5, 6: ER Insert, Spacers, and TruncOVA experimental
groups, respectively; Lanes 7, 8, 9) (b) To ensure that small amounts of inserted
construct was not outcompeted by the more numerous endogenous sequence for
polymerase, primers were designed to amplify from the 3’ end of the CMV promoter
to the 5’ end of the SV40 polyadenylation signal. Because this sequence is only
present in the donor DNA, successful amplification from FABF genomic DNA could
only occur if the donor DNA construct was successfully inserted. No bands were
observed for both the negative controls and experimental groups for each individual
construct. In contrast, bands of 341 bp (blue arrow), 368 bp (green arrow), and
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1130 bp (red arrow) are observed for amplification with ER Insert, Spacers, and
TruncOVA donor DNA as template, respectively.

Figure 5: Target17 Is an Inefficient sgRNA. The Surveyor nuclease cleaves
mismatched DNA, allowing quantification of the proportion of indels produced by
Cas9 cleavage at a given target site95,96. The Target17 target site was PCR amplified
and digested with the Surveyor nuclease. A distinct, smaller band alongside the
parental band therefore indicates the presence of indels produced by Cas9mediated target site cleavage. Greater intensity of the band representing the smaller
cleavage product indicates higher sgRNA efficiency. No band indicative of cleavage
by the Surveyor nuclease was observed in either a mock transfected control or FABF
cells transfected with Cas9 and Target17. A smaller band indicative of cleavage
(purple arrow) was observed in a positive control that came with the Surveyor
nuclease kit. Taken together, these results demonstrate that Target17 is an
inefficient sgRNA that does not significantly cleave its target site. Further, this result
explains why no insertion was observed at the target site – without target site
cleavage, the donor DNA cannot be used as a template for homology-directed repair.
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Identifier
TARGETSEQUENCE122
TARGETSEQUENCE11
TARGETSEQUENCE29
TARGETSEQUENCE47
TARGETSEQUENCE8
TARGETSEQUENCE97
TARGETSEQUENCE209
TARGETSEQUENCE15
TARGETSEQUENCE202
TARGETSEQUENCE60
TARGETSEQUENCE172
TARGETSEQUENCE134
TARGETSEQUENCE87
TARGETSEQUENCE115
TARGETSEQUENCE113
TARGETSEQUENCE61
TARGETSEQUENCE64
TARGETSEQUENCE168
TARGETSEQUENCE111
TARGETSEQUENCE31
TARGETSEQUENCE25
TARGETSEQUENCE152
TARGETSEQUENCE138
TARGETSEQUENCE46
TARGETSEQUENCE114
TARGETSEQUENCE49
TARGETSEQUENCE193
TARGETSEQUENCE39
TARGETSEQUENCE109
TARGETSEQUENCE17

Wild NeoPAM
Target Sequence
Predicted
Type
Efficiency
PAM
CAG
CGG
CAAGTTCAACGTGTGGGACA
9.0919
AGA
AGG
GAGGCCAGCCTGGTCTATAG 9.07017
TAG
TGG
CATCGCCAACTTCTCTGAGC 8.96595
TGA
TGG
TCATGCAGGCATCCGACGAG 8.90553
TTG
TGG
TCTCTATACCACTTCTCTAC 8.70791
GAG
GGG
CGGCTGCGGCGAGCGGGGAG 8.67553
GGT
GGG
TGCCGGCGACGGCTGGGTAT 8.61632
CCG
CGG
AGAGTCCTGCCGCTTCAAGG 8.55223
TGC
TGG
GTCCAAGAGCATGCAGTGAC 8.42117
CGA
CGG
TTCTGGGGTCTGATGAGCGT 8.25255
CTG
CGG
GTTTCCCGGAAGCTGCCCGG 8.17607
TTG
TGG
TGATGTTTCCAGTTATTTAT 8.15388
CTG
CGG
GGCGTCCCGCGGGCCGGCGC 8.14489
GGC
GGG
TGGAGGCTGCACAGTGCACA 8.12777
GTG
GGG
TTTTTTTGGTGTGTGTGTGT 8.10467
TTG
TGG
CTATGCTTACTGTTCTGTTT 8.08406
TGC
TGG
TGAAGAGGTCGTGGGGAATG 7.98259
CAG
CGG
ATTCCCAAGCAATCCGACTC 7.97552
AGA
AGG
GGAGCCTTCCTCTTTCTGTT 7.90524
CAG
CGG
CCAGGACTGAGCCTGGGGAC 7.90438
CAG
CGG
ACATCCATGGAGCTGTCAGC 7.88473
AGC
CGG
ACAGGGAAGTGCCTGTCGTG 7.82484
CTG
CGG
CGCCAGAAGCGAGAGCCCCT
7.8206
CAG
CGG
GCAGTTAAACATGGGTCAGT 7.78494
AGA
AGG
CTTTCAGAACGGGACCGCCG 7.59664
CGC
CGG
GGTGGAAGGCCACGAGCGCT 7.59237
TGC
TGG
CGGCCAGCTCCTGATGTTTC 7.57186
CGA
CGG
GCCGGCTTGCCCGATTTCCG 7.56243
AGT
AGG
CAAGGTCACCCTGGCTTACA 7.51026
AGC
AGG
TCGAGGCCGTCTCTATAAGT
6.3988

Table 1: 29 sgRNAs Have High Predicted Cleavage Efficiencies. 29
putative sgRNAs have predicted efficiency scores above the high efficiency
threshold of 7.5 according to the DRSC/TRiP CRISPR Efficiency Predictor tool. In
addition, Target Sequence 17, an sgRNA designed as part of an older pipeline that
did not take efficiency into account and did not mediate measurable gene knock-in
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(data not shown), has a score of 6.3988, well below the high efficiency threshold.
The six highest-scoring putative sgRNAs, hereafter referred to as sg1, sg2, sg3, sg4,
sg5, and sg6 in order of decreasing efficiency score, were chosen to have their
cleavage efficiencies evaluated in vitro.
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DISCUSSION
The results here demonstrate the critical importance of incorporating sgRNA
efficiency prediction and/or validation into sgRNA selection pipelines for any
therapeutic modality involving personalized gene editing with CRISPR/Cas9. When
efficiency is not taken into account, as was not the case with Target17 here, the
likelihood of a sufficient number of editing events occurring to induce a phenotypic
alteration or, presumably, a therapeutic response drops dramatically. Since both
PCR and CRPG cleavage by B3Z-produced β-galactosidase are capable of massively
magnifying small signals, it is highly unlikely that successful construct insertion and
expression off that inserted construct occurred but was at too low of a level to be
detected.
The immediate goal of this project moving forward will be to validate the
cleavage efficiencies of sg1, sg2, sg3, sg4, sg5, and/or sg6. Once it has been
demonstrated that neoPAMs are targetable with CRISPR/Cas9, designing a construct
that can be used as a template in homologous recombination and can express
SIINFEKL will be more of a technical challenge than a scientific one.
Therefore, the question of what effector polypeptide to express off the donor
DNA construct is worth considering. Suicide genes seem the obvious candidate, as
they are the best characterized and are capable of producing powerful bystander
effects that can help overcome the low efficiency of any in vivo gene editing protocol.
However, homologous recombination efficiency decreases markedly as insert size
increases97. Because suicide genes tend to be large enzymes, any insert containing a
suicide gene will be approaching the size limits of the CRISPR/Cas9 system. Thus,
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the efficiency of suicide gene insertion may be too low to mediate a significant
therapeutic effect, since small numbers of cells transfected will quickly be
eliminated before they can generate enough toxic metabolites to exert a bystander
effect.
Cytokines, in contrast, tend to be small genes that retain a potent antitumor
effect when released intratumorally by broadly activating immune cells and
promoting an inflammatory microenvironment. They are small enough that it may
be possible to express multiple cytokines divided by self-cleaving peptides off a
single promoter, thereby taking advantage of the combinatorial effects of multiple
pro-inflammatory cytokines being released into the local milieu. In addition,
because cytokines exert most of their cytotoxicity through immune cells that may or
may not attack the cell from which the cytokines were initially secreted, these
proteins are toxic to tumors overall but may not be as powerfully cytotoxic to
individual cells. This effect, if real, may magnify the bystander effect by allowing
cytokine-producing cells to remain in the tumor population longer.
B7 costimulatory ligands are also much smaller than suicide genes. Because
their expression on tumor cells can permit naïve T cells to become primed by tumor
cells directly without the need for an intermediary APC, they may be capable of
unleashing powerful CTL- or NK cell-mediated responses that can go on to eradicate
tumors locally and systemically. However, because they rely on CTLs and/or NK
cells to mediate their antitumor effects (except for tumors with MHC Class II
expression which can be controlled with CD4+ T cells alone), their insertion into
tumor cells may only be effective for tumors with functional MHC Class I
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presentation machinery. Further, because they are membrane-bound proteins, they
likely will induce primed CTLs and activated NK cells to quickly and efficiently kill
successfully edited tumor cells, severely limiting how many tumor-specific CTLs can
be primed by a single B7 costimulatory ligand-expressing tumor cell.
The two most significant challenges facing any in vivo gene editing strategy
are delivery and efficiency98. Techniques associated with Cas9 delivery are outside
the current scope of this project and hence will not be discussed here. The problem
of efficiency, however, is potentially tractable. Because the efficiency of gene knockin is inversely correlated with insert size, when choosing between two otherwise
equivalently effective strategies, the one that involves a smaller insert should be
chosen. More broadly, the problem associated with modifying tumor cells to express
cytotoxic genes is that too few cells in the tumor may be modified to produce a
bystander effect strong enough to destroy the tumor before the modified cells
themselves are eliminated. In other words, modifying tumor cells to express
cytotoxic genes produces a selective pressure that acts to remove those same tumor
cells, thereby allowing the tumor to escape. A gene editing strategy that reversed the
direction of the selective pressure to favor modified cells within the tumor might
therefore overcome low insertion efficiency by gradually increasing the allele
fraction of the modified locus in the tumor population.
There is, in fact, an analogous method used ubiquitously in molecular and
cellular biology to purify strains with a desired modification – selection of antibiotic
resistant clones. By linking the expression of a desired gene with an antibiotic
resistance gene, antibiotic selection creates selective pressure to express the
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desired gene. Thus, a construct that contains a resistance gene to a
chemotherapeutic compound and a suicide gene that exerts cytotoxicity through a
different mechanism than the chemotherapy might therefore enrich the tumor in
cells expressing the suicide gene. Inducing the suicide gene in a tumor enriched in
cells expressing the suicide gene would produce a significantly stronger bystander
effect far more likely to be capable of completely destroying the tumor.
(a)
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(b)

Figure 6: Model for Combining Resistance and Suicide Genes in Single
Constructs to Direct Tumor Evolution. (a) Two different constructs potentially
capable of directing tumor evolution by simultaneously providing resistance to one
cytotoxic agent and sensitizing tumor cells to another are shown. The order of these
genes in the construct is likely not relevant. These proteins could be expressed off
the same promoter by linking the polypeptides with self-cleaving viral 2A
peptides99,100 or internal ribosome entry site (IRES) elements101,102. (b) At first, not
many cells in a tumor are successfully edited. After the induction of the suicide gene
to which resistance has been provided or the start of chemotherapy, cells expressing
polypeptides from the construct grow unabated while the growth of unedited cells
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is significantly inhibited. Once a sufficient proportion of the tumor contains the
construct, the second suicide gene is induced, producing an overwhelming
bystander effect that wipes out the tumor.
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FUTURE DIRECTIONS
The most immediate priority is validating the cleavage efficiency of the six
sgRNAs with the highest predicted cleavage efficiency. Cleavage efficiency validation
will also be repeated with Target17 (sg7) to confirm it is inefficient, as the positive
control cleavage band intensity was lower than expected. Once cleavage efficiency
has been validated for the six sgRNAs, the highest efficiency sgRNA will be ordered.
New homology arms will be identified from the sequences flanking the target site in
the mm10 reference genome and used to design new donor DNA sequences as
previously described.
The ability of these donor DNA constructs to generate SIINFEKL that can be
presented on the FABF cell surface will be assayed as previously described and
compared. Once the best donor DNA construct has been identified, the ability of
edited FABF cells to elicit anti-SIINFEKL responses in vivo will be investigated. The
magnitude of the bystander effect whereby anti-SIINFEKL responses lead to a
generalized antitumor immune response will be quantified. These experiments will
be repeated in a different tumor cell line that does not contain the targeted neoPAM
to demonstrate that the editing event is truly restricted to cells harboring the
mutation.
After demonstrating the effectiveness of neoPAM knock-in by inserting a
SIINFEKL-producing construct into FABF, multiple different antitumor strategies
outlined above will be investigated. In particular, TK007 and a bicistronic construct
expressing interferon-γ and IL-2 will be knocked into tumor cells separately. Bulk
edited cells will be used to form tumors in mice and their growth will be monitored
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to assess the magnitude of the constructs’ antitumor effects. Finally, a polycistronic
construct will be generated that will express cytosine deaminase, the 5-FU
metabolizing enzyme DPYD103, and TK007. These cells will be used to form tumors
in mice that will be treated with first with 5-FC and later with ganciclovir.
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APPENDIX I: PREDICTED GUIDE RNA EFFICIENCIES OF TARGETABLE SNVS IN
FABF EXOME
Identifier
TARGETSEQUENCE122
TARGETSEQUENCE11
TARGETSEQUENCE29
TARGETSEQUENCE47
TARGETSEQUENCE8
TARGETSEQUENCE97
TARGETSEQUENCE209
TARGETSEQUENCE15
TARGETSEQUENCE202
TARGETSEQUENCE60
TARGETSEQUENCE172
TARGETSEQUENCE134
TARGETSEQUENCE87
TARGETSEQUENCE115
TARGETSEQUENCE113
TARGETSEQUENCE61
TARGETSEQUENCE64
TARGETSEQUENCE168
TARGETSEQUENCE111
TARGETSEQUENCE31
TARGETSEQUENCE25
TARGETSEQUENCE152
TARGETSEQUENCE138
TARGETSEQUENCE46
TARGETSEQUENCE114
TARGETSEQUENCE49
TARGETSEQUENCE193
TARGETSEQUENCE39
TARGETSEQUENCE109
TARGETSEQUENCE48
TARGETSEQUENCE165
TARGETSEQUENCE118
TARGETSEQUENCE28
TARGETSEQUENCE184
TARGETSEQUENCE207
TARGETSEQUENCE18
TARGETSEQUENCE99
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Wild
Type
PAM
CAG
AGA
TAG
TGA
TTG
GAG
GGT
CCG
TGC
CGA
CTG
TTG
CTG
GGC
GTG
TTG
TGC
CAG
AGA
CAG
CAG
AGC
CTG
CAG
AGA
CGC
TGC
CGA
AGT
AGT
GCG
GGC
GGA
AGC
AGA
TGT
TTG

NeoPAM

Target Sequence

Predicted
Efficiency

CGG
AGG
TGG
TGG
TGG
GGG
GGG
CGG
TGG
CGG
CGG
TGG
CGG
GGG
GGG
TGG
TGG
CGG
AGG
CGG
CGG
AGG
CGG
CGG
AGG
CGG
TGG
CGG
AGG
AGG
GGG
GGG
GGG
AGG
AGG
TGG
TGG

CAAGTTCAACGTGTGGGACA
GAGGCCAGCCTGGTCTATAG
CATCGCCAACTTCTCTGAGC
TCATGCAGGCATCCGACGAG
TCTCTATACCACTTCTCTAC
CGGCTGCGGCGAGCGGGGAG
TGCCGGCGACGGCTGGGTAT
AGAGTCCTGCCGCTTCAAGG
GTCCAAGAGCATGCAGTGAC
TTCTGGGGTCTGATGAGCGT
GTTTCCCGGAAGCTGCCCGG
TGATGTTTCCAGTTATTTAT
GGCGTCCCGCGGGCCGGCGC
TGGAGGCTGCACAGTGCACA
TTTTTTTGGTGTGTGTGTGT
CTATGCTTACTGTTCTGTTT
TGAAGAGGTCGTGGGGAATG
ATTCCCAAGCAATCCGACTC
GGAGCCTTCCTCTTTCTGTT
CCAGGACTGAGCCTGGGGAC
ACATCCATGGAGCTGTCAGC
ACAGGGAAGTGCCTGTCGTG
CGCCAGAAGCGAGAGCCCCT
GCAGTTAAACATGGGTCAGT
CTTTCAGAACGGGACCGCCG
GGTGGAAGGCCACGAGCGCT
CGGCCAGCTCCTGATGTTTC
GCCGGCTTGCCCGATTTCCG
CAAGGTCACCCTGGCTTACA
TTCCATGGACCGATGGACTG
CACGAGCGGCGCCGGGGAGT
AAGACAAGGGCTCTGATGGG
GTCCTGTTCCCATTGATGGT
AGCAAGCAGCCTACCAGGCT
TGGACAGTGGCCATGGAAGT
CATGGAAGACTCGATGGATA
TCTGTTGGCCGAGGTGAGTC

9.0919
9.07017
8.96595
8.90553
8.70791
8.67553
8.61632
8.55223
8.42117
8.25255
8.17607
8.15388
8.14489
8.12777
8.10467
8.08406
7.98259
7.97552
7.90524
7.90438
7.88473
7.82484
7.8206
7.78494
7.59664
7.59237
7.57186
7.56243
7.51026
7.49501
7.48202
7.47718
7.35056
7.329
7.31052
7.24548
7.21284
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TARGETSEQUENCE179
TARGETSEQUENCE176
TARGETSEQUENCE86
TARGETSEQUENCE57
TARGETSEQUENCE7
TARGETSEQUENCE90
TARGETSEQUENCE12
TARGETSEQUENCE27
TARGETSEQUENCE100
TARGETSEQUENCE156
TARGETSEQUENCE131
TARGETSEQUENCE162
TARGETSEQUENCE145
TARGETSEQUENCE91
TARGETSEQUENCE82
TARGETSEQUENCE101
TARGETSEQUENCE70
TARGETSEQUENCE20
TARGETSEQUENCE53
TARGETSEQUENCE112
TARGETSEQUENCE85
TARGETSEQUENCE169
TARGETSEQUENCE79
TARGETSEQUENCE35
TARGETSEQUENCE208
TARGETSEQUENCE158
TARGETSEQUENCE30
TARGETSEQUENCE210
TARGETSEQUENCE181
TARGETSEQUENCE124
TARGETSEQUENCE155
TARGETSEQUENCE10
TARGETSEQUENCE175
TARGETSEQUENCE201
TARGETSEQUENCE133
TARGETSEQUENCE166
TARGETSEQUENCE105
TARGETSEQUENCE38
TARGETSEQUENCE17
TARGETSEQUENCE40
TARGETSEQUENCE192
TARGETSEQUENCE147
TARGETSEQUENCE174
TARGETSEQUENCE76
Englander

AGC
TGA
CGT
CCG
TGC
CTG
GTG
AGC
GGC
TGT
AAG
CGC
TGC
CAG
AGC
GGA
TGC
CAG
AGC
GGC
GGA
GGA
AAG
ATG
CAG
TTG
AGC
CAG
TTG
CAG
CCG
AAG
CTG
GGC
CAG
CAG
GTG
GAG
AGC
AGA
CGA
GGA
AGC
CAG

AGG
TGG
CGG
CGG
TGG
CGG
GGG
AGG
GGG
TGG
AGG
CGG
TGG
CGG
AGG
GGG
TGG
CGG
AGG
GGG
GGG
GGG
AGG
AGG
CGG
TGG
AGG
CGG
TGG
CGG
CGG
AGG
CGG
GGG
CGG
CGG
GGG
GGG
AGG
AGG
CGG
GGG
AGG
CGG

CATACCAGGCTTTGAAAGGC
CCTCCTGTTATTATGGGGTC
GGGGTGGGGGGTGGGGGACC
GGCAAGAAGCGCAAGCGCAG
ACAAGTGTACTAGCAGTCTG
CTAGGCATTCCTCCCTCCCT
CTCTGGAGGACAGTCCATCA
CATGGTCTCCAGCCTGGCCC
GGGCGGGCGGAGGCCGCAGC
CTTCCGGCTCTCTACATGCT
CCACCAAGTCACGCACCAAA
TCCCGTGGCCATCATACCCC
TTGCTAATTACCGTCTCTTC
CGCTGGCAGAACGAGAAGAG
TTCTCCCCGATGCTGGACAC
CCGGGGACGGAGGGGAGAGC
GCTCTCCTCGGGGTCAATGA
GAGCCAGGGATAATCTGAGT
TTCTTCTTTGATTTCTTTTC
GAAGCGGCCCATAAAGGGGG
GTGGGGGACCCGTCGTCTGT
GCTCGGCTCTTCCTGGAGTC
TCTGTTACGCAGAGTTAAGA
GCACGCACACAGTCCATGGC
AGTTGTTACACACTCCTTAG
TATTAAGATGGTCTCCCAGC
ACCTTATCCCCAGGCGGAAC
TGGAGCGTGGGGACCATACC
CATTATCTGCCCTAAGATGT
CTGGTGGGCGACGGCAGCAC
CGAGGAGCCCGACCTCCCCC
AAGTGGATCTGGCTGAAGTG
GTCACTGTCGCCTTGATTTC
TCCCTCCTCAGGGTTCCCCT
AACGGAATGGATGAAGGTTA
GGCGCGCCGGGGGCCGCGAC
CCGTGTCCCCGCCGCCGCCA
AGTCGCCCAAGAGGGCTGAG
TCGAGGCCGTCTCTATAAGT
AACCCGCGACCGGCACCGAC
TGCGGCGACCGCTCTTGTGA
CGTGGCGGCGCTGCTGGCCG
GTACTGGTTTTCCTCCCAGC
GGGAGACTGAGGGCCCGGCC

7.18283
7.17312
7.16004
7.14979
7.13917
7.13758
7.12872
7.10614
7.0806
7.04131
7.01241
6.99684
6.98089
6.96332
6.95848
6.90135
6.85213
6.84996
6.81477
6.81466
6.77051
6.74216
6.73532
6.73034
6.69514
6.68536
6.67683
6.57391
6.54838
6.52535
6.51818
6.49663
6.49193
6.48417
6.48375
6.47819
6.46101
6.43311
6.3988
6.36686
6.35608
6.34633
6.31684
6.28109
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TARGETSEQUENCE62
TARGETSEQUENCE203
TARGETSEQUENCE160
TARGETSEQUENCE4
TARGETSEQUENCE66
TARGETSEQUENCE173
TARGETSEQUENCE65
TARGETSEQUENCE125
TARGETSEQUENCE96
TARGETSEQUENCE80
TARGETSEQUENCE13
TARGETSEQUENCE44
TARGETSEQUENCE170
TARGETSEQUENCE144
TARGETSEQUENCE83
TARGETSEQUENCE204
TARGETSEQUENCE187
TARGETSEQUENCE127
TARGETSEQUENCE129
TARGETSEQUENCE69
TARGETSEQUENCE74
TARGETSEQUENCE58
TARGETSEQUENCE67
TARGETSEQUENCE183
TARGETSEQUENCE81
TARGETSEQUENCE104
TARGETSEQUENCE77
TARGETSEQUENCE6
TARGETSEQUENCE199
TARGETSEQUENCE157
TARGETSEQUENCE45
TARGETSEQUENCE102
TARGETSEQUENCE23
TARGETSEQUENCE151
TARGETSEQUENCE191
TARGETSEQUENCE185
TARGETSEQUENCE136
TARGETSEQUENCE188
TARGETSEQUENCE182
TARGETSEQUENCE68
TARGETSEQUENCE132
TARGETSEQUENCE72
TARGETSEQUENCE200
TARGETSEQUENCE205
Englander

CTG
GGC
CAG
TTG
AAG
TTG
AAG
CAG
CGC
CAG
CCG
CAG
CTG
GGC
CCG
ACG
TAG
CGC
CAG
CAG
ATG
AGC
AGC
TCG
GCG
GAG
CTG
TAG
AAG
CTG
CAG
CAG
CGC
TCG
CCG
CTG
CAG
CAG
TGC
TGA
CCG
ATG
GGA
AAG

CGG
GGG
CGG
TGG
AGG
TGG
AGG
CGG
CGG
CGG
CGG
CGG
CGG
GGG
CGG
AGG
TGG
CGG
CGG
CGG
AGG
AGG
AGG
TGG
GGG
GGG
CGG
TGG
AGG
CGG
CGG
CGG
CGG
TGG
CGG
CGG
CGG
CGG
TGG
TGG
CGG
AGG
GGG
AGG

AATGCAGCATCTGCGATGTG
GTCACTAGGGATGCAATGGG
TTTCCCATGAACAAAAGAAC
CATCCACTTCCTTCAGTGTA
ACCTGAAACCCCAAAGCAAA
GTAGCCTCTTGCATCAGCTC
TGAGAACCAACTTTCCCAAC
CTCGTCCTGGTGGGCGACGG
GGGGCCGTCGTGTTTCGGGT
GCTCTAAGGGCTGGGTCTGA
TGAGTGTCCCATCCTGAGCT
CAAGGCACGTGCCCCTCTCT
TGAAACCGTTAAGAGGTAAA
CTCACTAGTCTTCCCCAAGT
GCATGACTGGAGAGGCCAGC
CAGCGTGCACTGAAAAGAGG
TTCTTCCTCTTCATTCGCCC
AAGGACTCCTGCTTCTGCTT
CGCGGCCCGGACCGTCGCGG
GCCACCTCCATCTTGTTGTG
TTAATGAGCCTCCGAAGAGT
ACTTCTTGGAACAATGTGTC
CCAGTTTAAGAGTTGGGTGA
TAGGTGGAAGTCTTCTACTC
GTAGATGGACCGAAGGATCA
ACACACAAGACGGGGAGAGC
CACGTCTGAACTTTGGGAGA
CTGCAATCAGCACTGGCTCT
TGTTGGTTGATATAGACAGC
TTTGAGTTTGCTGGGGGAAG
CGGGTTCAGATCCCCAAATC
CGGGTTTTGTCGGACCCCGA
AGCTCTTACCGTTGTCACAC
AAAGGACAGGGAAGTGCCTG
CGAAGTTGGTGGGGAAAAAG
GGCAGCTACTCTCTTCACAT
AACGGGCTTGGCGGAATCAG
CCTGAGTTCGTAGGCGCAGC
CATCTTGGCTCCGCTCTGAC
CTGCTCCTCGTCTCGGCCTC
GAAGACGGGTCAGCTGAGGT
TCATGGCGCACAGCCTCTGG
AGGAAGTCTCTTTAAGAAAA
CTTTCCCTTTTTTCCAAAGG

6.25101
6.23212
6.22627
6.22058
6.20832
6.18684
6.18632
6.17893
6.12515
6.12091
6.11728
6.09946
6.0761
6.06224
6.05279
6.02901
5.99791
5.9431
5.9013
5.88761
5.86874
5.85862
5.78629
5.77796
5.74471
5.71338
5.70015
5.67779
5.62602
5.62123
5.5684
5.5511
5.53652
5.52926
5.52594
5.49995
5.44758
5.43718
5.37512
5.25009
5.21881
5.21703
5.20918
5.2061
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TARGETSEQUENCE141
TARGETSEQUENCE51
TARGETSEQUENCE56
TARGETSEQUENCE164
TARGETSEQUENCE5
TARGETSEQUENCE78
TARGETSEQUENCE110
TARGETSEQUENCE137
TARGETSEQUENCE161
TARGETSEQUENCE94
TARGETSEQUENCE36
TARGETSEQUENCE92
TARGETSEQUENCE98
TARGETSEQUENCE143
TARGETSEQUENCE108
TARGETSEQUENCE189
TARGETSEQUENCE128
TARGETSEQUENCE153
TARGETSEQUENCE89
TARGETSEQUENCE171
TARGETSEQUENCE194
TARGETSEQUENCE34
TARGETSEQUENCE54
TARGETSEQUENCE148
TARGETSEQUENCE52
TARGETSEQUENCE32
TARGETSEQUENCE146
TARGETSEQUENCE135
TARGETSEQUENCE71
TARGETSEQUENCE21
TARGETSEQUENCE139
TARGETSEQUENCE19
TARGETSEQUENCE163
TARGETSEQUENCE24
TARGETSEQUENCE59
TARGETSEQUENCE149
TARGETSEQUENCE197
TARGETSEQUENCE121
TARGETSEQUENCE117
TARGETSEQUENCE93
TARGETSEQUENCE42
TARGETSEQUENCE22
TARGETSEQUENCE107
TARGETSEQUENCE167
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GGC
TCG
CGC
ACG
GGA
TGT
AGC
GAG
CCG
CTG
ACG
GGA
GAG
CAG
TAG
CCG
CAG
TGC
AGA
CAG
AAG
CGC
CCG
CAG
AGC
GCG
CCG
GGT
CCG
CGC
GGC
AAG
CTG
TGC
AGA
AGC
TGA
AGC
AAG
TCG
AGC
TTG
CAG
GGC

GGG
TGG
CGG
AGG
GGG
TGG
AGG
GGG
CGG
CGG
AGG
GGG
GGG
CGG
TGG
CGG
CGG
TGG
AGG
CGG
AGG
CGG
CGG
CGG
AGG
GGG
CGG
GGG
CGG
CGG
GGG
AGG
CGG
TGG
AGG
AGG
TGG
AGG
AGG
TGG
AGG
TGG
CGG
GGG

TAGGCAGAATTTGCTCCCCT
CGTGCATGAGAAAAGAGCCG
TTTGAGGACACCAACCTGTG
GGCGGTCTTGGCCAGGTGGC
AACCATGCGGTAGCTCTTGC
CGGGAAAACGCAGGGTTGTA
TGTGGCGTTATGTATACTAA
CCGACCCCGACGCGAGGACG
TCTGAAGCAGATAGACCAGG
GAACTCGGAGCGGGGAGGCG
GTCCCCAGGTTCCCAGGGTC
CGGAGGCACACCAGGGAATG
GGTCAGTCAGAGGAGAGGGG
CCCAGAAAGGCAACGTGACT
TTCAGTCATAATCCCACAGA
AGGAATGCCAGTCGCAGCTG
GGGGGCATCGGCAGAAGGGG
ATGGTTCCGATGCCCCACAT
AGCGGCCGCGTGCGGCGCAA
AACGATGCCGACTGGTGATG
TTCAGCTCATACTCGGGTGG
GAACTCCTCGAAGCCCAGCA
GCTCCTGCGACCTGCTGCTA
CACCTAGTGGTGACAAGTTT
CTTCTTCTATTTCCTTTTCC
TTACCATCACCATCGGAGCA
CTAGAAGCAAGTGAAGCCGA
GAGAAAGACATAGATGTGCC
GCCACCTCTTCTGCCTGCAG
GACACACTGAAGTCCAAGTA
AGAGGGGAAGAGTAGAAAGA
GGAAAGCGATCTGCTCCTGG
CTGGTCGTTGCGACTTCGTC
GGATATGCAGGAGCTGGAAG
CTTCTACTATGACCAGTGCG
ACCTAGTGGTGACAAGTTTC
ATTTTCACAGCTAGTTGATT
GTCTCTCCCTGGGGACTCCG
ACCATACACTCATTAAAAGA
GTCTCTCCCGAATGGTCCCC
CCCTTGAAAATCCGGGGGAG
GCGCATTTTTGTGGTGGGTT
GAGCTTTGGAAATCCCAGCG
GCCCCCGGCGCGCCGGGCTC

5.1969
5.18665
5.13792
5.13594
5.13309
5.13107
5.12674
5.11605
5.08964
5.08578
5.0781
5.0759
5.06516
5.06346
5.02782
5.01306
5.00173
4.98881
4.93993
4.89998
4.89753
4.89131
4.82327
4.80408
4.77708
4.77594
4.75457
4.73426
4.72597
4.72112
4.71344
4.70543
4.6899
4.68434
4.67399
4.65943
4.65266
4.62262
4.60744
4.60179
4.58036
4.50944
4.49144
4.46064
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TARGETSEQUENCE154
TARGETSEQUENCE73
TARGETSEQUENCE130
TARGETSEQUENCE177
TARGETSEQUENCE195
TARGETSEQUENCE9
TARGETSEQUENCE95
TARGETSEQUENCE26
TARGETSEQUENCE159
TARGETSEQUENCE41
TARGETSEQUENCE190
TARGETSEQUENCE178
TARGETSEQUENCE33
TARGETSEQUENCE84
TARGETSEQUENCE150
TARGETSEQUENCE43
TARGETSEQUENCE180
TARGETSEQUENCE1
TARGETSEQUENCE119
TARGETSEQUENCE103
TARGETSEQUENCE37
TARGETSEQUENCE196
TARGETSEQUENCE14
TARGETSEQUENCE123
TARGETSEQUENCE126
TARGETSEQUENCE63
TARGETSEQUENCE120
TARGETSEQUENCE140
TARGETSEQUENCE198
TARGETSEQUENCE116
TARGETSEQUENCE88
TARGETSEQUENCE106
TARGETSEQUENCE75
TARGETSEQUENCE142
TARGETSEQUENCE2
TARGETSEQUENCE186
TARGETSEQUENCE16
TARGETSEQUENCE3
TARGETSEQUENCE55
TARGETSEQUENCE50
TARGETSEQUENCE206
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GGT
TGC
CCG
CGC
AGC
TGA
AAG
TGA
TGC
CCG
GCG
GCG
TCG
GGC
TGA
CGT
TCG
TGA
TGC
CAG
TGC
CAG
TGC
TAG
CGC
CAG
CCG
TGA
TGT
TAG
GGC
ATG
GAG
CAG
AAG
TGC
CCG
TAG
CAG
AAG
CAG

GGG
TGG
CGG
CGG
AGG
TGG
AGG
TGG
TGG
CGG
GGG
GGG
TGG
GGG
TGG
CGG
TGG
TGG
TGG
CGG
TGG
CGG
TGG
TGG
CGG
CGG
CGG
TGG
TGG
TGG
GGG
AGG
GGG
CGG
AGG
TGG
CGG
TGG
CGG
AGG
CGG

CACATGAACGGGCGGTCTCC
ATGATGGTTTTCCGAAGCTT
CACCCACTCTCTCGCTGCTC
AGGTTTTTCTCCGATTCAGA
GCTCGTGGAAGATGTCTTCC
GGCCAGTGTCCCTCTCACAC
CACGGACCCTCTCGACCCCG
AGCCTGACCTCCCAGGAGAG
GGGAGATGGGGCCCAAATCA
GGTTCGGGAGCGGAAAAAGA
CTCCTTGATGGCTGGTGTAA
ACCTTCTTCACCCAGCCTAA
GAGAGCCTTGGGCACCAGAA
CTGTGGATTGTGCGTCCCGG
CAAAGCTCCTGGTCCCCGGT
CCATGACGCTTTCCAAGGCA
GGATCCCGTACTTCTCCAGC
GAATAACATTGAGAATTTAA
CCAGCCTGAGAGTATCTCCC
AACGGGAGAGTGCATGCGGC
AAGCCTGCAGTGAACCTCCA
TCCAGCACCATCCATTTTCA
GGCCAGCCAGGGAGGCTCCC
GAACTTGATGGGTCCTCTGT
GTGATTCCCATCAAAAGTGC
TGTCTTTTTGGATGGCGTCA
TCCCCCTCCTCCACGTGAGT
GTGGGTGATGTCTGTGAAGA
GGTTGATATAGACAGCAAGA
ATGCTCCCTTCCCCTTACTG
CAGAGATGAAGAAAAGCCAA
GCTTCTTATACTTGAGGTCC
TGGTGAACTATGCCTGGGCA
TAGTCTGGTGCTTCTGAGGC
TGGCTTTAATCTCCTTCAGC
TCCCAGGCTGGGAGTCCCAT
GCCAATGGTGCCAGAATTCA
GGAATTGAATGAACACAGCC
GCAGAACTTATTTGAGAGGC
AAAAAAAAAATCCAAAGCCG
TAAAAATCATTAAAAATGGA

4.44428
4.43532
4.43252
4.43023
4.4277
4.42154
4.37757
4.33787
4.33521
4.31398
4.31297
4.31239
4.25377
4.24152
4.23858
4.22658
4.20347
4.20293
4.15624
4.12085
4.06205
4.0254
4.00327
3.93871
3.9386
3.92324
3.88766
3.84887
3.77935
3.76858
3.76649
3.75764
3.72089
3.68784
3.64992
3.64314
3.54109
3.4996
3.43438
3.33545
2.67133
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APPENDIX II: DONOR DNA, SGRNA, AND PRIMER SEQUENCES
ER Insert:
>5' homology arm (482)
GTTACCAGGCTATCCCTAGACCTTGCCATAACTCCTGGCACATAGGGGATGCTCACACAA
GCCTATTAACTTTGTAAAGCAAAATTTCATGGGACGTTTCATAATGTGAATTTCTCCTA
AAATAAGTCAGAAGCAAAACCAGCAAAAGAGGCAGCATTTCTTTATTACCTGCAATTAG
TCATTTGCATGGTACAAAGAGGTGAAAAGTTTCAGATACATGATTTGGATGAATTGATT
TTTAAAGATTTTACTTTTATTATTTTTACTGTGTGTGTGCATACATGTGTGTGTATGCAC
TCCTGTGCATGTGTGTGCACACACAGGCACCTACTTGAGTATAGGTGCCTACAAAATCTG
GAAGACAACACTGGATTCCTGGTAGCTGGAATCACCGAAGGCTGTGATACAGGTGCTGG
GGAGTCCTTTACCAATGAGCTGCATCTCAGGATCTGGGGCACGCCTTCTCACAGAGGACA
CTGTCC
>CMV enhancer (304)
CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATT
GACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCA
ATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCC
AAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTA
CATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTAC
CATG
>CMV promoter (204)
GTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATT
TCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGA
CTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACG
GTGGGAGGTCTATATAAGCAGAGCT
>Kozak sequence (9)
GCCGCCACC
>E3/19K ER insertion signal with N-terminal Met (51)
ATGAGGTACATGATCCTGGGCCTGCTGGCCCTGGCCGCCGTGTGCAGCGCC
>SIINFEKL (24)
AGCATCATCAACTTCGAGAAGCTG
>Stop codon (3)
TGA
>SV40 PolyA Signal (122)
AACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCAC
AAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATC
TTA
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>3' homology arm (424)
GGTTTCTGATGTACTCCCGGTACATGGCAGTGTCCTCTTTGCCAAGGGGCTGCATGATAC
CTTGGCTAGCTTGGATATGGGCCTGGAAGATCTCTGTAGACTTTCTGTCTACTCTTGGAG
GCTGAACTTCATAAATGTTGTCTTGCGAGAAAGCTGAGATGGGAGTTCTGTAAAAGAGG
AAAGACAGGACTGTGTTATGGAACTTCTCACCACAACATGGGCTTCACCAACCAAGGGCA
ACCTCTGCAGTTGTTACTTCCTGGGAGGCCAAAGGATAGAAGCTGTCCCTGATACCCAGG
CAGGGCAGAGGTCCTGTCCCTTATAGAATGTCAGCTCTATAGTTGCGTGTCCTGCTGGCT
CCCACTGGAAGAAGCTTCAGGTGGTACTATACCTAAGTTTTGTTCCTTGTCCTTGCAGGC
TCTTG
Spacers:
>5' homology arm (482)
GTTACCAGGCTATCCCTAGACCTTGCCATAACTCCTGGCACATAGGGGATGCTCACACAA
GCCTATTAACTTTGTAAAGCAAAATTTCATGGGACGTTTCATAATGTGAATTTCTCCTA
AAATAAGTCAGAAGCAAAACCAGCAAAAGAGGCAGCATTTCTTTATTACCTGCAATTAG
TCATTTGCATGGTACAAAGAGGTGAAAAGTTTCAGATACATGATTTGGATGAATTGATT
TTTAAAGATTTTACTTTTATTATTTTTACTGTGTGTGTGCATACATGTGTGTGTATGCAC
TCCTGTGCATGTGTGTGCACACACAGGCACCTACTTGAGTATAGGTGCCTACAAAATCTG
GAAGACAACACTGGATTCCTGGTAGCTGGAATCACCGAAGGCTGTGATACAGGTGCTGG
GGAGTCCTTTACCAATGAGCTGCATCTCAGGATCTGGGGCACGCCTTCTCACAGAGGACA
CTGTCC
>CMV enhancer (304)
CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATT
GACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCA
ATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCC
AAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTA
CATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTAC
CATG
>CMV promoter (204)
GTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATT
TCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGA
CTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACG
GTGGGAGGTCTATATAAGCAGAGCT
>Kozak sequence (9)
GCCGCCACC
>SIINFEKL plus spacer (102)
ATGGCCGTGCTGCTGCCCGACGAGGTGAGCGGCCTGGAGCAGCTGGAGAGCATCATCAAC
TTCGAGAAGCTGACCGAGTGGACCAGCAGCAACGTGATGGAG
Englander
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>Stop codon (3)
TGA
>SV40 PolyA Signal (122)
AACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCAC
AAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATC
TTA
>3' homology arm (424)
GGTTTCTGATGTACTCCCGGTACATGGCAGTGTCCTCTTTGCCAAGGGGCTGCATGATAC
CTTGGCTAGCTTGGATATGGGCCTGGAAGATCTCTGTAGACTTTCTGTCTACTCTTGGAG
GCTGAACTTCATAAATGTTGTCTTGCGAGAAAGCTGAGATGGGAGTTCTGTAAAAGAGG
AAAGACAGGACTGTGTTATGGAACTTCTCACCACAACATGGGCTTCACCAACCAAGGGCA
ACCTCTGCAGTTGTTACTTCCTGGGAGGCCAAAGGATAGAAGCTGTCCCTGATACCCAGG
CAGGGCAGAGGTCCTGTCCCTTATAGAATGTCAGCTCTATAGTTGCGTGTCCTGCTGGCT
CCCACTGGAAGAAGCTTCAGGTGGTACTATACCTAAGTTTTGTTCCTTGTCCTTGCAGGC
TCTTG
TruncOVA:
>5' homology arm (482)
GTTACCAGGCTATCCCTAGACCTTGCCATAACTCCTGGCACATAGGGGATGCTCACACAA
GCCTATTAACTTTGTAAAGCAAAATTTCATGGGACGTTTCATAATGTGAATTTCTCCTA
AAATAAGTCAGAAGCAAAACCAGCAAAAGAGGCAGCATTTCTTTATTACCTGCAATTAG
TCATTTGCATGGTACAAAGAGGTGAAAAGTTTCAGATACATGATTTGGATGAATTGATT
TTTAAAGATTTTACTTTTATTATTTTTACTGTGTGTGTGCATACATGTGTGTGTATGCAC
TCCTGTGCATGTGTGTGCACACACAGGCACCTACTTGAGTATAGGTGCCTACAAAATCTG
GAAGACAACACTGGATTCCTGGTAGCTGGAATCACCGAAGGCTGTGATACAGGTGCTGG
GGAGTCCTTTACCAATGAGCTGCATCTCAGGATCTGGGGCACGCCTTCTCACAGAGGACA
CTGTCC
>CMV enhancer (304)
CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATT
GACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCA
ATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCC
AAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTA
CATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTAC
CATG
>CMV promoter (204)
GTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATT
TCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGA
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CTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACG
GTGGGAGGTCTATATAAGCAGAGCT
>Kozak sequence (9)
GCCGCCACC
>Truncated Ovalbumin (864)
ATGGGCAGCCTGGCCAGCAGACTGTACGCCGAGGAGAGATACCCCATCCTGCCCGAGTAC
CTGCAGTGCGTGAAGGAGCTGTACAGAGGCGGCCTGGAGCCCATCAACTTCCAGACCGCC
GCCGACCAGGCCAGAGAGCTGATCAACAGCTGGGTGGAGAGCCAGACCAACGGCATCATC
AGAAACGTGCTGCAGCCCAGCAGCGTGGACAGCCAGACCGCCATGGTGCTGGTGAACGCC
ATCGTGTTCAAGGGCCTGTGGGAGAAGGCCTTCAAGGACGAGGACACCCAGGCCATGCCC
TTCAGAGTGACCGAGCAGGAGAGCAAGCCCGTGCAGATGATGTACCAGATCGGCCTGTTC
AGAGTGGCCAGCATGGCCAGCGAGAAGATGAAGATCCTGGAGCTGCCCTTCGCCAGCGGC
ACCATGAGCATGCTGGTGCTGCTGCCCGACGAGGTGAGCGGCCTGGAGCAGCTGGAGAGC
ATCATCAACTTCGAGAAGCTGACCGAGTGGACCAGCAGCAACGTGATGGAGGAGAGAAA
GATCAAGGTGTACCTGCCCAGAATGAAGATGGAGGAGAAGTACAACCTGACCAGCGTGC
TGATGGCCATGGGCATCACCGACGTGTTCAGCAGCAGCGCCAACCTGAGCGGCATCAGCA
GCGCCGAGAGCCTGAAGATCAGCCAGGCCGTGCACGCCGCCCACGCCGAGATCAACGAGG
CCGGCAGAGAGGTGGTGGGCAGCGCCGAGGCCGGCGTGGACGCCGCCAGCGTGAGCGAGG
AGTTCAGAGCCGACCACCCCTTCCTGTTCTGCATCAAGCACATCGCCACCAACGCCGTGCT
GTTCTTCGGCAGATGCGTGAGCCCC
>Stop codon (3)
TGA
>SV40 PolyA Signal (122)
AACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCAC
AAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATC
TTA
>3' homology arm (424)
GGTTTCTGATGTACTCCCGGTACATGGCAGTGTCCTCTTTGCCAAGGGGCTGCATGATAC
CTTGGCTAGCTTGGATATGGGCCTGGAAGATCTCTGTAGACTTTCTGTCTACTCTTGGAG
GCTGAACTTCATAAATGTTGTCTTGCGAGAAAGCTGAGATGGGAGTTCTGTAAAAGAGG
AAAGACAGGACTGTGTTATGGAACTTCTCACCACAACATGGGCTTCACCAACCAAGGGCA
ACCTCTGCAGTTGTTACTTCCTGGGAGGCCAAAGGATAGAAGCTGTCCCTGATACCCAGG
CAGGGCAGAGGTCCTGTCCCTTATAGAATGTCAGCTCTATAGTTGCGTGTCCTGCTGGCT
CCCACTGGAAGAAGCTTCAGGTGGTACTATACCTAAGTTTTGTTCCTTGTCCTTGCAGGC
TCTTG
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sgRNAs:
sgRNA Name
sg1
sg2
sg3
sg4
sg5
sg6
sg7

Target Sequence
CAAGTTCAACGTGTGGGACA
GAGGCCAGCCTGGTCTATAG
CATCGCCAACTTCTCTGAGC
TCATGCAGGCATCCGACGAG
TCTCTATACCACTTCTCTAC
CGGCTGCGGCGAGCGGGGAG
TCGAGGCCGTCTCTATAAGT

NeoPAM
CGG
AGG
TGG
TGG
TGG
GGG
AGG

Primers:
Experiment
Donor DNA
Amplification
(Fig. 4a)
SIINFEKLSpecific
Amplification
(Fig. 4b)
Cleavage
Validation
(sg1)
Cleavage
Validation
(sg2)
Cleavage
Validation
(sg3)
Cleavage
Validation
(sg4)
Cleavage
Validation
(sg5)
Cleavage
Validation
(sg6)
Cleavage
Validation
(sg7)
Englander

Forward Primer

Reverse Primer

GGGTGGCCTATGGAGGT

CAAGAGCCTGCAAGGACAA

GTGATGCGGTTTTGGC

GTGATGCTATTGCTTTATTTGTAACC

GTATGTAGCCACCCTGGG

GGCAACAAACTCCAAGTTAGG

TAATAGGTCGCCGGGC

TCAGGTCTTAGCAAATGCAA

GGATACCAGACACCGTGAAC

GCCCCTCTGAATCACATC

GCTGAAGCCCAGCAAAGA

TGACGCTTTCCAAGGCA

TACACATCGACAGCCCAA

GCACAAGAACAGGACACACT

TTCCCGAAGGACGACAG

CAGTGTGATTCCCGCC

CCGAAGGCTGTGATACAGG

GCTTCTTCCAGTGGGAGC
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